Last 5 Days Trading Activity
|Date||Open Price||Close Price||High||Low||Volume|
Last 5 Days Short Activity
|Date||Short Volume||Total Volume||Short Percentage||Short Indicator|
* Short Mode
About Urologix, Inc. (OTC: ULGX)
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia BPH . Urologix Cooled ThermoTherapy produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
- Scott Madson / CFO
- Lisa Ackermann / EVP, Sales amp Mkt.
- Gregogy J Fluet / Administrator
- Christopher R Barys /
- Mitchell Dann /
- Sidney W Emery, Jr /
- Patrick D Spangler /
Current Share Structure
- Market Cap: $39,272 - 03/16/2018
- Authorized: 30,000,000 - 04/28/2015
- Issue and Outstanding: 21,817,726 - 05/01/2015
Daily Technical Chart for (OTC: ULGX)
Stay tuned for daily updates and more on (OTC: ULGX)
More to come on (OTC: ULGX)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ULGX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ULGX and does not buy, sell, or trade any shares of ULGX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/